Search results
Results from the WOW.Com Content Network
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
Dementia-like symptoms have been found in some individuals who have been exposed to glucocorticoid medication, often dispensed in the form of asthma, arthritis, and anti-inflammatory steroid. [2] The term "steroid dementia" was coined by Varney et al. (1984) in reference to the effects of long-term glucocorticoid use in 1,500 patients. [3]
Barium is a soft, silvery-white metal, with a slight golden shade when ultrapure. [9]: 2 The silvery-white color of barium metal rapidly vanishes upon oxidation in air yielding a dark gray layer containing the oxide. Barium has a medium specific weight and high electrical conductivity. Because barium is difficult to purify, many of its ...
The CDC said 1.7% of adults ages 65 to 74 reported a dementia diagnosis, a rate that increased with age. For those ages 75 to 84, the reported dementia rate was 5.7%
Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care. Without the ability to reliably assess dementia across the board, the misuse of anti-dementia compounds could have negative consequences, such as patients receiving the wrong medication, or not receiving treatment in the early stages of ...
Signs and symptoms are classified into three groups based on the affected functions of the frontal and temporal lobes: [8] These are behavioural variant frontotemporal dementia, semantic dementia, and progressive nonfluent aphasia. An overlap between symptoms can occur as the disease progresses and spreads through the brain regions. [14]
The Saint Louis University Mental Status (SLUMS) Exam is a brief screening assessment used to detect cognitive impairment. [1] It was developed in 2006 at the Saint Louis University School of Medicine Division of Geriatric Medicine, in affiliation with a Veterans' Affairs medical center. [2]
ARIA-E refers to cerebral edema, involving the breakdown of the tight endothelial junctions of the blood-brain barrier and subsequent accumulation of fluid. [3] In a double-blind trial of the humanised monoclonal antibody solanezumab (n = 2042), sixteen patients (11 taking the drug, 5 taking a placebo), or 0.78% developed ARIA-E.